Naifencon® Was Included in the "Chinese Adult IgA Nephropathy and IgA Vasculitis Clinical Practice Guidelines (Preliminary Version)"

The pre-reviewed version of the guideline recommends 9 months of budesonide enteric-coated capsules for causal treatment in patients with IgA nephropathy at risk of disease progression, regardless of proteinuria levels. As a causal treatment drug for IgA nephropathy that targets the intestinal mucosa, Naifencon® has definite efficacy and good safety, providing a new treatment option for patients with IgA nephropathy. A new management strategy th…

Everest Medicines Announces NEFECON® Inclusion in China’s Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)

SHANGHAI, May 23, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the “Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)” (hereinafter referred to as […]